PMI Promotion of IQOS Using FDA MRTP Order

This page was last edited on at

In December 2016, Philip Morris International (PMI) applied to the U.S. Food and Drug Administration (FDA) to have IQOS, its heated tobacco product (HTP), classified as a Modified Risk Tobacco Product (MRTP) in the US.12 The US Tobacco Products Advisory Committee (TPSAC) recommended against approving PMI’s application to market IQOS as a reduced risk product.3

On 7 July 2020, the US Federal Drug Administration (FDA) announced its ruling.456  It granted an ‘exposure modification’ order, which allows PMI to market IQOS in the U.S. using the following claims:4

  • “The IQOS system heats tobacco but does not burn it”
  • “This significantly reduces the production of harmful and potentially harmful chemicals”
  • “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals”

The FDA denied PMI a ‘risk modification’ order, for which PMI originally applied. A ‘risk modification’ order requires a burden of proof that products “(1) Significantly reduce harm and the risk of tobacco-related disease to individual tobacco users; and (2) Benefit the health of the population as a whole taking into account both users of tobacco products and persons who do not currently use tobacco products”. PMI “did not demonstrate” that IQOS met these standards. The exposure modification standard that PMI was awarded “establishes a lower standard” than that of risk modification.7

PMI’s press release and a statement from CEO André Calantzopoulos hailed the ruling as a “historic public health milestone”. PMI focussed on the granted exposure modification order while limiting reference to the denied risk modification order.5

In July 2020, the Tobacco Control Research Group (TCRG) at the University of Bath produced a STOP briefing, summarising the evidence from academic research on IQOS, and highlighting the potential for the misrepresentation of the partial approval applying to the marketing of IQOS, which only applies in the US.8 In September 2020, TCRG researchers additionally published a peer-reviewed paper in BMJ highlighting how the decision increases confusion around the safety of HTPs.9

The FDA decision has been quoted in news media worldwide, with examples collected by TobaccoTactics from the following countries: Algeria,10 Argentina,111213 Bahrain,14 Canada,15 Colombia,16 Costa Rica,17 Croatia,18 Cyprus,192021 Ecuador,22 Egypt,23242526 France,27 Georgia,28 Honduras,29 Hong Kong,30313233 Indonesia,3435 Italy,36 Jordan,37 Kenya,38 Lebanon,39 Malaysia,4041 Malta,42 Mexico,434445464748 Moldova,49 Nigeria, 505152535455 Palestine,5657 Pakistan,58 Philippines,59606162636465 Romania,66 Russia,6768 Rwanda,69 Spain,70 South Africa,717273 South Korea,74757677 Sweden,78 Tanzania,79 United Arab Emirates,80 United States,8182 Uruguay,83 Vietnam,848586 Zambia,87 Zimbabwe.888990 This list it not exhaustive, and it is important to note that any inaccuracies in articles authored by international journalists do not represent violations of the granted exposure order by PMI.

Decision misconstrued in global news media

While many of these reports mimic the celebratory, but technically FDA-compliant, narrative provided in PMI’s media releases and interview statements, there are multiple instances of inaccurate journalistic reporting. Duty Free News International ran an article on 14 July 2020 with the headline “Milestone’ decision as FDA Approves IQOS as Modified Risk Tobacco Product”; the FDA has not “approved” IQOS (see above).91 Various other publications in trade journals (Market Watch 6), investor publications (The Motley Fool92 – later retracted) local news outlets (Honduras’ La Prensa,29 Hong Kong’s The Standard,30 Moldova’s KP,49 Nigeria’s The Sun50; and broadly, coverage across EMR in Algeria,10 Bahrain,14 Egypt,242526 and Jordan37) and pro-tobacco industry think tanks (US-based Reason Foundation81) made similar claims about the product being “safer” than cigarettes. It is incorrect to say IQOS is “safe”, or to imply that IQOS poses a reduced risk of harm when in fact it has only been shown to reduce exposure.

PMI uses FDA decision to lobby for regulatory change

In addition to calling the decision a “historic public health milestone”,5 PMI is transparent in its desire to use the FDA decision to advocate for legislative change. In its press release immediately following the decision, PMI CEO Calantzopolous said:5

“The FDA’s decision provides an important example of how governments and public health organizations can regulate smoke-free alternatives to differentiate them from cigarettes in order to promote the public health.”

Countries are at different stages in their regulation of HTPs; some have banned them outright, many have allowed their sale under certain regulatory conditions, and in others the regulatory position remains unclear. There are also wide variations in taxation rates.93 At COP 8 in 2018, parties to the WHO Framework Convention on Tobacco Control (FCTC) agreed to regulate HTPs as tobacco products.94 For more information and links to external resources, see the main page on Heated Tobacco Products.

In some regions, local PMI directors and managers have used the FDA decision to explicitly lobby for changes to regulations of tobacco products:

  • Canada: Rothmans, Benson & Hedges Inc. (PMI affiliate) in Canada used the decision to advocate for “risk-based regulation” of tobacco products in the country, where it claimed “[r]egulation in Canada has not kept pace with innovation of smoke-free technologies”.15
  • Hong Kong: The manager of PMI Hong Kong & Macau, Brett Cooper, said that he hoped to have “dialogue” and “conversation” on the regulation of alternative smoking products, also known as next generation products (NGPs). An article in The Harbour Times suggested that the FDA decision would encourage legislators reconsider a proposed ban on NGPs.32 The Standard reported, quoting CEO Calantzopolous, that PMI “urged authorities worldwide to ‘maximize adoption of these products by adult smokers,’ adding that if not, ‘we would be missing an enormous public health opportunity’”.31
  • Latin America: In an interview with Forbes in Mexico, Mario Masseroli, President of PMI Latin America and Canada, said PMI had “been in contact with the Mexican authorities trying to show the difference between IQOS and conventional cigarettes” and that “you cannot ignore a decision like the FDA” (translated from original Spanish).48 HTPs were banned in Mexico in February 2020, by presidential order.95 Masseroli made similar statements in Argentina,11 Colombia,16 Honduras29 and Uruguay.83 On 1 September 2020, the Mexican government put out a statement in response to the FDA decision and PMI statements made in the country, which reaffirmed its decision to ban the import of HTPs and clarified that IQOS was not granted “reduced risk” status, in the US or in Mexico.96
  • Nigeria: An interview with Bahman Safakish, Managing Director for PMI Sub-Saharan Africa, began to appear in Nigerian news media at the end of July. In what appears to be its first run in The Sun, the article was briefly titled “Why we can’t stop selling cigarettes – Philip Morris Int’l” (30 July) before changing to “Our plans to end cigarette smoking – Philip Morris Int’l” (31 July), and stated that ending cigarette sales “would automatically create a niche market for competitors and illicit trades who do not appreciate the need replace the combustible hazardous smoking with the electronic vapour-producing device that is much safer health-wise”, giving this as the reason why the company would not stop selling cigarettes “despite global health concerns”.50545397 Note that the FDA decision did not conclude that IQOS was “safer” than traditional cigarettes, or that it reduces risk.
  • Philippines: An article detailing an interview with PMI Asia director Stacey Kennedy encouraged the country to adopt the US FDA decision as a “starting block” to provide “the basis of public health policymaking”.65 The article also claimed IQOS was a “reduced risk” product, and is “less harmful than traditional cigarettes”. This is false; FDA actually denied PMI’s reduced risk application (see above).
  • South Africa: PMI used the FDA decision as an additional argument against the ban on tobacco products that was imposed in the country as a result of the COVID-19 pandemic. Philip Morris South Africa (PMSA) that said that the continuing ban on tobacco products was a “missed opportunity to make smoke-free alternatives available for 11-million South African smokers”, citing the FDA decision as evidence that IQOS is a “much better choice than continued smoking”.71 A comment from PMSA in the online magazine TWFLD said that it encouraged the South African government to follow a “science-based approach” in its policy-making and advised it adopt “a similar regulatory approach to the U.S. FDA”.72
  • South Korea: An article titled “Following FDA’s decision, PMI repeats need for differentiated policies” appeared in The Korea Herald on 13 July 2020, again quoting the CEO: “Making a comparison to fossil fuels and coal, Calantzopoulos urged that governments around the world should provide differentiated policies for conventional cigarettes and heated tobacco products”.74 PMI Korea CEO Paik Young-jay held an online news conference in September 2020, in which he said: “The FDA’s decision is an important example of how governments and public health agencies can regulate heat-not-burn products and cigarettes differently to improve public health” and recommended “rational regulation”.75 A further article in The Korea Herald covering the conference, initially titled “Philip Morris Korea says Iqos brings ‘reduced risk’”, included both modified and reduced risk claims, misrepresenting the FDA decision.76 Within hours, this article was corrected, instead appearing as “Philip Morris aims to acquire ‘risk modification’ nod from FDA”.77

Relevant Links

TobaccoTactics Resources

TCRG Research

References

  1. L. Wheeler, Tobacco giant asks the FDA to approve ‘less risky’ cigarette, thehill.com, 23 August 2017, accessed August 2020
  2. L.K. Lempert, S. Glantz, Heated tobacco product regulation under US law and the FCTC, Tobacco Control, 2018;27(Suppl 1):s118-s125, doi:10.1136/tobaccocontrol-2018-054560
  3. Y. Abutaleb, U.S. senators ask FDA to reject Philip Morris’ IQOS application, Reuters, 7 February 2018, accessed February 2018
  4. abFood and Drug Administration, FDA Authorizes Marketing of IQOS Tobacco Heating System with ‘Reduced Exposure’ Information, FDA.gov, 7 July 2020, accessed July 2020
  5. abcdPhilip Morris International, FDA Authorizes Marketing of IQOS as a Modified Risk Tobacco Product, PMI website, 7 July 2020, accessed July 2020
  6. abT. Garcia, Philip Morris gets FDA approval to market its ‘tobacco heating system’ as a healthier alternative to smoking, MarketWatch, 7 July 2020, accessed July 2020
  7. Food and Drug Administration, Scientific Review of Modified Risk Tobacco Product Application (MRTPA), July 2020
  8. S. Braznell, A.B. Gilmore, A. Rowell, FDA does not rule that IQOS reduces tobacco-related harm, yet PMI still claims victory, STOP briefing, August 2020
  9. A.B. Gilmore, S. Braznell, US regulator adds to confusion around heated tobacco productsBMJ, 2020;370:m3528, doi:10.1136/bmj.m3528
  10. abLicencing of Philip Morris to market modified risk tobacco products (translated from Arabic), Elmihwar, 14 July 2020, accessed August 2020
  11. abT.R. Ansorena, La FDA autoriza a Philip Morris a vender sus dispositivos Iqos como una mejor alternativa al cigarrillo, Forbes Argentina, 7 July 2020, accessed August 2020
  12. La alternativa al cigarrillo que obtuvo el visto bueno de Estados Unidos, El Cronista, 7 July 2020, accessed July 2020
  13. G. Grimaldi, Decisión de EE.UU. abre una puerta para la llegada del dispositivo de tabaco calentado, baenegocios, 16 July 2020, accessed August 2020
  14. abFDA permits marketing of heated tobacco products with modified risk (translated from Arabic), Alwatan, 16 July 2020, accessed August 2020
  15. abRothmans, Benson & Hedges Inc., Historic FDA Ruling Should Prompt Canadian Governments to Review Tobacco Regulation: RBH, PRNewswire, 9 July 2020, accessed August 2020
  16. ab“En América Latina se prohíben los productos como IQOS, pero sí están aprobados los cigarrillos tradicionales que se sabe causan más daño”: Mario Masseroli, presidente de PMI en América Latina y Canadá, Despejando Dudas, 18 July 2020, accessed August 2020
  17. Philip Morris Costa Rica anunció la llegada de su dispositivo electrónico IQOS, Revista Summa, 12 October 2020, accessed October 2020
  18. Nothing will be the same anymore: Find out what hardened smokers will face in the next 10 years. And no, it doesn’t have to be as black as you think (translated from Croatian), Zena, 28 September 2020, accessed September 2020
  19. Offsite Team, IQOS is licensed by the FDA (translated from Greek), Offsite, 22 July 2020, accessed July 2020
  20. IQOS licensed by the FDA as a Differentiated Hazardous Tobacco Product (translated from Greek), Alpha News, 23 September 2020, accessed September 2020
  21. Why did the FDA license IQOS as a Differentiated Risk tobacco product (translated from Greek), Philenews, 28 September 2020, accessed September 2020
  22. Este es el cigarrillo electrónico cuyo uso fue autorizado por la FDA como “riesgo modificado”, El Universo, 11 July 2020, accessed July 2020
  23. FDA authorizes marketing of Philip Morris’s IQOS towards a smoke-free future, Amwal Al Ghad English, 12 July 2020, accessed July 2020
  24. abM. Abd al-Ati, Food and Drug Administration “announces official marketing” authorization for heated tobacco products as modified risk products (translated from Arabic), Almasry Alyourn, 12 July 2020, accessed August 2020
  25. abA. Khairy, The US Food and Drug Administration officially permits the marketing of heated tobacco products (translated from Arabic), Gomhuria Online, 12 July 2020, accessed August 2020
  26. abM. Obaid, Philip Morris receives approval for marketing risk-adjusted tobacco in America (translated from Arabic), Al Wafd, 15 July 2020, accessed August 2020
  27. Philip Morris France S.A.S., La FDA américaine autorise la commercialisation aux Etats-Unis d’IQOS et de ses recharges de tabac en tant que « produit du tabac à risque modifié » (MRTP), Revue des Tabacs, 9 July 2020, accessed August 2020
  28. Philip Morris Allowed to Label IQOS as Reducing Harmful Exposure, Georgia Today, 14 July 2020, accessed July 2020
  29. abcSistema de fumado alternativo recibe autorización de la FDA en EEUU, La Prensa, 17 July 2020, accessed August 2020
  30. abPhilip Morris to end cigarette sales in favor of heated tobacco product, The Standard, 13 July 2020
  31. abM. Zheng, Vaping easing historic moment for public health, The Standard, 14 July 2020, accessed July 2020
  32. abT. Chow, FDA statement on IQOS may prevent ban on alternative smoking products in Hong Kong, Harbour Times, 20 July 2020, accessed July 2020
  33. HKEJ, FDA authorizes Philip Morris’s IQOS products, EJInsight, 10 July 2020, accessed July 2020
  34. FDA permits IQOS, Here’s Sampoerna’s Response (translated from Indonesian), Warta Ekonomi.co.id, 16 July 2020, accessed August 2020
  35. US Food and Drug Administration: Alternative Tobacco Product Regulation Needs to be Science Based (translated from Indonesian), Warta Ekonomi, 6 October 2020, accessed October 2020
  36. S. Veli, Philip Morris e IQOS, l’accisa che brucia, il manifesto, 26 August 2020, accessed August 2020
  37. abAfter the American Food Decision…CEO Philip Morris: A historic decision (translated from Arabic), Jordan Zad News, 18 July 2020, accessed August 2020
  38. V. Manyeki, Why Kenya needs to proactively engage tobacco harm reduction, The Star, 23 July 2020, accessed July 2020
  39. Philip Morris Lebanon, Lebanon’s Digital Leap into a Smoke-Free Future, Daily Star, 24 July 2020, accessed July 2020
  40. J. Choong, Philip Morris Malaysia welcomes US agency’s decision on marketing IQOS system as historic milestone, Malay Mail, 9 July 2020, accessed July 2020
  41. D. Lam, Regulate tobacco products according to the risks they pose, New Straits Times, 14 August 2020, accessed November 2020
  42. Philip Morris receives FDA authorisation to market IQOS in US, Times Malta, 15 August 2020, accessed August 2020
  43. FDA determina que cigarro que no combustiona tiene menos riesgos que el tradicional, 24 Horas, 11 July 2020, accessed July 2020
  44. Redacción Animal Político, Piden nueva regulación para producto alternativo de Philip Morris, Animal Político, 3 August 2020, accessed August 2020
  45. La FDA le da el sí a IQOS de Philip Morris, Expansión, 7 July 2020, accessed July 2020
  46. 5 razones por las que la autorización de IQOS por la FDA es benéfica, Bolsamanía, 9 July 2020, accessed August 2020
  47. Philip Morris México, 5 razones por las que la autorización de IQOS por la FDA es benéfica, PR Newswire, 8 July 2020, accessed August 2020
  48. abS. Sánchez, Philip Morris confía en pronta venta de su IQOS en México tras reconocimiento de FDA, Forbes México, 16 July 2020, accessed July 2020
  49. abPhilip Morris Moldova director: regulatory policy must take into account risk factors for tobacco products (translated from Russian), kp.md, 29 July 2020, accessed July 2020
  50. abcU. Usim, Why we can’t stop selling cigarettes – Philip Morris Int’l, The Sun, 30 July 2020, accessed July 2020
  51. C. Muanya, Concerns over modified risk tobacco products as WHO employs AI to help people quit smoking, The Guardian Nigeria, 16 July 2020, accessed July 2020
  52. FDA authorises marketing of IQOS as modified risk tobacco product, EnviroNews Nigeria, 10 July 2020, accessed August 2020
  53. abInside Business, Sound Regulation Will Help Bring About a Smoke-Free World – Philip Morris MD, Inside Business, 3 August 2020, accessed August 2020
  54. abD. Adekanmbi, Why We Want To Stop Cigarette Sale – Safakish, Philip Morris MD, Nigerian Tribune, 2 August 2020, accessed August 2020
  55. P. Jakpor, Unending Drama About So-called Safe Alternatives To Cigarettes, The New Diplomat, 24 August 2020, accessed August 2020
  56. Branco Civarlik Highlights the Philip Morris International Journey (translated from Arabic), Alhadath, 7 September, accessed September 2020
  57. The United States Food and Drug Administration (US FDA) permits marketing of Philip Morris International’s IQOS product in the United States of America as an MRTP product (translated from Arabic), Wattan, 27 October 2020, accessed October 2020
  58. US-FDA authorizes marketing of IQOS as a ‘modified risk tobacco product’, Tribune, 9 July 2020, accessed August 2020
  59. USFDA authorizes IQOS as ‘Modified Risk Tobacco Product’, Philippine News Agency, 9 July 2020, accessed July 2020
  60. J.A. Gamboa, Reducing health risks through science, Manila Bulletin, 15 July 2020, accessed August 2020
  61. US FDA authorizes marketing of IQOS as Modified Risk Tobacco Product, Manila Bulletin, 8 July 2020, accessed August 2020
  62. I. Ocampo Flora, Philip Morris: Combustion, not nicotine, is the problem, Sun Star Pampanga, 18 July 2020, accessed July 2020
  63. Associated Press, FDA: Marketing modified tobacco product okay, The Manila Times, 19 July 2020, accessed July 2020
  64. Heated tobacco products will benefit public health, Manila Bulletin, 16 August 2020, accessed August 2020
  65. abC.S. Leyco, Philip Morris urges PH to adopt US FDA finding, Manila Bulletin, 7 September 2020, accessed September 2020
  66. Administrația pentru Alimente si Medicamente (FDA) din Statele Unite a autorizat comercializarea IQOS ca produs din tutun cu risc modificat, Agerpres, 8 July 2020, accessed August 2020
  67. L. Bezuglova, FDA Issued a Resolution on the Sale IQOS as a Product with Reduced Exposure (translated from Russian), White Square Journal, 21 August 2020, accessed August 2020
  68. D. Smirnov, FDA Approves Sale of IQOS in US as a Reduced Exposure Product (translated from Russian), High Tech, 26 August 2020, accessed August 2020
  69. Times Reporter, FEATURED: FDA authorizes marketing of IQOS Tobacco Heating System with ‘reduced exposure’ information, The New Times, 13 July 2020, accessed August 2020
  70. EP, Madrid, La FDA de EE.UU. autoriza que se comercialice el IQOS de Philip Morris, La Vanguardia, 9 July 2020, accessed July 2020
  71. abTobacco ban is a missed opportunity to create smoke-free SA – PMSA, iol.co.za, 24 July 2020, accessed July 2020
  72. abP. Mabele, IQOS can be marketed as Modified Risk Tobacco Product; FDA, TWFLD, 14 July 2020, accessed August 2020
  73. ’Strong science’ claimed to be behind FDA decision to permit IQOS marketing, Medical Brief, 15 July 2020, accessed August 2020
  74. abJ. He-rim, Following FDA’s decision, PMI repeats need for differentiated policies, The Korea Herald, 13 July 2020, accessed July 2020
  75. abL. Han-Soo, ‘FDA designation of IQOS as modified risk should change regulatory regime’, Korea Biomedical Review, 9 September 2020, accessed September 2020
  76. abY. Hyun-su, Philip Morris Korea says Iqos brings ‘reduced risk’, The Korea Herald, 9 September 2020, accessed September 2020
  77. abY. Hyun-su, Philip Morris aims to acquire ‘risk modification’ nod from FDA, The Korea Herald, 9 September 2020, accessed September 2020
  78. FDA Authorizes Marketing of IQOS as Modified Risk Tobacco Product, Via TT, 7 July 2020, accessed August 2020
  79. S. Satigul, Lessons for Africa after historic US FDA decision, The Citizen, 15 July 2020, accessed August 2020
  80. N. Webster, UAE doctors warn against smoke-free cigarettes after US approves their promotion, The National, 13 July 2020, accessed July 2020
  81. abG. Bentley, FDA Says IQOS Tobacco Products Reduce Exposure to Harmful Chemicals Found in Cigarette Smoke, Reason Foundation, 7 July 2020, accessed August 2020
  82. D. Caruana, The FDA Authorizes the Marketing of IQOS as a Modified Risk Tobacco Product, Vaping Post, 30 July 2020, accessed August 2020
  83. abM. Malek, IQOS tiene aval de FDA, pero es ilegal en Uruguay, El Pais, 19 July 2020, accessed August 2020
  84. FDA cấp phép cho PMI kinh doanh sản phẩm IQOS dưới thông tin “giảm thiểu sự phơi nhiễm”, Công Thuong, 13 July 2020, accessed August 2020
  85. Philip Morris được phép công bố IQOS là sản phẩm giảm thiểu sự phơi nhiễm, Lao Dông, 9 July 2020, accessed August 2020
  86. T. Dung, FDA nỗ lực kiểm soát thuốc lá để bảo vệ sức khỏe cộng đồng, Vietnam Plus, 17 September 2020, accessed September 2020
  87. Staff Writer, Modified risk tobacco products and the future of smoking, The Independent Observer, 20 October 2020, accessed October 2020
  88. E. Mushava, Boost for Zim’s tobacco industry, The Zimbabwe Daily, 20 July 2020, accessed July 2020
  89. Mwebantu Editor, US okays electronic cigarettes, mwebantu.com, 7 August 2020, accessed August 2020
  90. Business Reporter, Golden expectations for tobacco sector, Sunday Mail, 13 September 2020, accessed September 2020
  91. C. Madden, ‘Milestone’ Decision as FDA Approves IQOS as Modified Risk Tobacco Product, DFNI, 14 July 2020, accessed July 2020
  92. R. Duprey, IQOS’ Reduced-Risk Label Victory Shows Altria’s Dual E-Cig Track Was the Smart Play, The Motley Fool, 15 July 2020, accessed July 2020
  93. Institute for Global Tobacco Control, Countries That Regulate Heated Tobacco, globaltobaccocontrol.org, accessed July 2020
  94. World Health Organisation, Conference of the Parties to the WHO Framework Convention on Tobacco Control, DECISION FCTC/COP8(22) Novel and emerging tobacco products, Geneva, Switzerland, 6 October 2018, accessed July 2020
  95. FCTC Secretariat, Mexico prohibits the import of electronic cigarettes and heated tobacco products, 19 February 2020, accessed July 2020
  96. Government of Mexico, Ministry of Health Statement [in Spanish], COFEPRIS website, 1 September 2020, accessed September 2020
  97. U. Usim, Our plans to end cigarette smoking – Philip Morris Int’l, The Sun, 31 July 2020, accessed July 2020